Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + CRT and Conversion Surgery for Locally Advanced Unresectable ESCC
NCT07039162Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC). Started Sep 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07039162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07039162.